Clinical trial
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory…
NCT00003414 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00003414 |
|---|---|
| Title | Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease |
| Official title | Randomized Trial of Autologous GVHD for Refractory Lymphoma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease, Lymphoma |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy |
| Enrollment | 50 |
| Start date | Oct 1, 1997 |
| Primary completion | May 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Dec 2, 2003 |
| Last update posted | Jul 20, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: